Barclays PLC Buys 11,748 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Barclays PLC grew its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 18.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 75,395 shares of the company’s stock after acquiring an additional 11,748 shares during the quarter. Barclays PLC owned 0.11% of Zentalis Pharmaceuticals worth $277,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ZNTL. Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Paloma Partners Management Co purchased a new position in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Aigen Investment Management LP purchased a new position in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $41,000. Capstone Investment Advisors LLC purchased a new position in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $48,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after acquiring an additional 5,333 shares in the last quarter.

Analyst Ratings Changes

Several research analysts recently commented on ZNTL shares. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Guggenheim decreased their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Trading Up 8.0 %

Shares of Zentalis Pharmaceuticals stock opened at $3.24 on Monday. The company’s fifty day simple moving average is $3.33 and its two-hundred day simple moving average is $3.50. The company has a market cap of $230.90 million, a P/E ratio of -1.30 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a 12-month low of $2.66 and a 12-month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.